AbbVie Inc. (NYSE:ABBV) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

AbbVie logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate AbbVie “Moderate Buy”: Of 29 analysts, 22 recommend buying, one gives a strong-buy rating and six recommend holding; the average 12-month price target is $297.85.
  • AbbVie beat quarterly estimates, reporting adjusted EPS of $3.82 versus $3.73 expected and revenue of $17.40 billion versus $17.32 billion. Revenue rose 10.3% year over year.
  • The company raised its quarterly dividend from $1.73 to $1.82 per share, equivalent to $7.28 annually and a 2.5% yield.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-nine analysts that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $297.85.

A number of brokerages have recently weighed in on ABBV. Weiss Ratings raised shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. The Goldman Sachs Group raised their target price on AbbVie from $258.00 to $294.00 and gave the stock a "neutral" rating in a research note on Friday, October 23rd. Cantor Fitzgerald lifted their price target on AbbVie from $290.00 to $325.00 and gave the stock an "overweight" rating in a research report on Monday, November 2nd. BMO Capital Markets set a $315.00 price target on AbbVie in a research report on Wednesday, November 4th. Finally, Piper Sandler boosted their price target on AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th.

Get Our Latest Stock Analysis on ABBV

AbbVie Stock Down 0.7%

ABBV stock opened at $292.40 on Wednesday. The stock has a market capitalization of $516.85 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. AbbVie has a 52 week low of $190.75 and a 52 week high of $302.93. The firm has a 50 day moving average of $277.14 and a 200 day moving average of $241.64.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. AbbVie's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.86 EPS. On average, equities research analysts expect that AbbVie will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a $1.82 dividend. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie's previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie's dividend payout ratio (DPR) is 119.10%.

Insider Activity at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company's stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Hedge Funds Weigh In On AbbVie

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Financial Freedom LLC purchased a new position in shares of AbbVie during the third quarter worth $29,000. Burk Holdings LLC acquired a new position in AbbVie during the second quarter valued at $30,000. Marquette Asset Management LLC boosted its holdings in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after purchasing an additional 48 shares during the last quarter. Principia Wealth Advisory LLC boosted its holdings in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Finally, IMG Wealth Management Inc. grew its position in AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock worth $40,000 after purchasing an additional 153 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

More AbbVie News

Investors following ABBV have been watching these news items:

AbbVie Company Profile

(Get Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Read More

Analyst Recommendations for AbbVie (NYSE:ABBV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines